eHealth First: For Platform for Personalized Health
For healthy people, patients and health professionals
Medical doctor (M.D., Stavropol State Medical Academy), Ph.D. (K.M.N., Immunology and Allergy, NRC Institute of Immunology FMBA Russia), Master of Public Health (M.P.H., Hebrew University of Jerusalem, Israel), Master of Business Administration (M.B.A., International Business School MIRBIS).
He has11 years of experience in pharmaceutical industry (as senior manager, head of department and C.E.O., 40+ completed projects of drug registration and clinical studies) and 20 years of experience in biomedical research, 6 junior researcher awards.
Nickolay is a founder and C.E.O. of R&D and service group of companies Clinical Excellence Group (registration of pharmaceuticals, food supplements, medical devices, clinical, non-clinical and observational studies, data analysis, strategic planning), operated in the Eurasian Economic Union and the European Union (from 2012).
He is an editor and co-author of Russia's first multimedia Course on Biostatistics, which was recommended by Organizational and methodological union of Russian High schools (Universities) on medical and pharmaceutical education for medical under- and postgraduates (2006), editor and co-author of Evidence-based Guideline for People living with HIV/AIDS, healthcare providers and public health professionals (2009).
He was a member of the Advisory Board of the Quality of Life (Health) project of the State Duma of the Federal Assembly of the Russian Federation (2010-2011), а member of the Advisory Board on the Reform and Modernization of the Healthcare System and Demographics Policy of the Civic Chamber of the Russian Federation (2012).
Nickolay is an author of 64 publications in Russian and International peer-reviewed journals and Conference Abstract Books, expert in healthcare for Russian media (TVC, 1TV, MIR, MIR 24, TV 360, OTR). His Biography is included in Marquis Who's Who in the World, 2012-2016 (29th-33rd editions) and 2000 Outstanding intellectuals of the 21st century, 2012-2015 (7th-10th editions).
Advisor in Mathematical Modeling of complex biomedical systems, Systems Biology of the aging process, Advanced Data Analysis.
Ph.D., Research Professor of Medicine at the Dalhousie University, Halifax, Canada. He is a multidisciplinary scientist with research Interest in mathematical modeling of complex biomedical systems / systems biology of the aging process, and advanced data analysis.
Prof. Mitnitski is known for the development of the Frailty Index (FI, suggested together with Dr. K. Rockwood in 2001). The FI integrates a large amount of individual's health information (generally available in typical databases) in a single number and related to the biological age of the individuals. This FI is universally accepted as a valuable utility measure of health in individuals and populations which allows to stratify people by the risk of adverse outcomes (mortality, entering nursing home, time spending in hospital, etc.). It has numerous applications in a variety of areas, including epidemiology, clinical medicine, biology, and most recently even macro-economics. The FI has a strong theoretical foundation in a stochastic dynamic model of deficit accumulation based on the organism- environment interaction. Most recently, a new approach based on the complex dynamical network (being developed with the colleagues of the Department of Physics) allowed bringing the theoretical understanding of the origin of the FI to the next level.
Dr. Mitnitski published over 200 peer reviewed papers (most of them for the last 15 years), 136 are available in the PubMed, 23 papers were sited over 100 times; his (most conservative) Thomson Reuters h-index=40 (Google Scholar h-index=49). He is a member of the editorial boards/associate editor of the scientific journals: Biogerontology, BMC Geriatrics, Frontiers in Public Health, Journal of Aging Science, and a reviewer for the large number of journals, including Experimental Gerontology, Mechanisms of Ageing and Development, Journal of Gerontology, Age and Ageing, Demography. He is also a member of the College of Reviewers for the Canadian Institute of Health Research (CIHR). Being an elected Fellow of the Gerontological Society of America (GSA), he organized several symposia at the GSA annual meetings related to the Systems Biology of Aging and the Biological Age determination.
Director, Public Health and Longevity Programs
Daria is a Board Member of the International Longevity Alliance and the Chair of the Board of the Russian Regional Russian NGO "Council for Public Health and Demography".
She received Ph.D. in anthropology, and after a few years of academic career she gradually moved into the area of public health advocacy, including anti-liquor and anti-tobacco control in Russia and internationally.
She currently works at promoting regulation beneficial for biomedical R&D, especially in the area of curing and preventing pathologies of aging. Daria is currently a coordinator of "Healthy Longevity" segment of the Russian National Technological Initiative.
She is the head of the Group of the Monitoring of Global and Regional Risks of the Russian Academy of Sciences, co-chairperson of the Russian Coalition for Alcohol Control, as well as the Russian Coalition for Tobacco Control. She is a laureate of the Russian Science Support Foundation Award in "The Best Economists of the Russian Academy of Sciences" nomination (2006).
Advisor in Health Policy and Management, Clinical Epidemiology, Public Policy, eHealth, Clinical Neurology, Clinical Diagnostics, Clinical Studies, Aging and Longevity Studies
Dr. Guldemond is Assoc. Prof. Integrated Care & Technology at the Institute Health Policy and Management, Erasmus University Rotterdam, the Netherlands.
He is policy advisor for the Health Ministry and consultant for various organisations: WHO, EU Programmes EIT KIC Health, KIC Digital, AAL, IMI and H2020. He is active numerous eHealth programmes: China, UK, Russian Federation, Italy, Norway, Poland, Germany, Belgium, Brazil, Iran, Finland, Romania and US. Often in collaboration with industry Pharma (Roche, Genzyme, J&J, Grunenthal), Medtech (Philips, MEDTRONIC, COCIR), Health IT (Microsoft, Ascom, Ortec, Vodafone) and finance (Rabobank, Natwest, RBS).
He was architect of the national eHealth and Big Data strategy. He is coordinator of EU EIP on Healthy and Active Ageing and member of the ISO Strategic Advisory Group on Ageing Societies.
Nick has a background in Electric Engineering, Medicine and Life Sciences. He was CEO & founder of the Medical Field Lab ie health innovation, for which he obtained prestigious research grants. He worked on innovation and medical curriculum development for different universities.
Advisor in Biomedical Gerontology, Aging and Longevity Studies, Biotechnology, Drug Assessment, Health Promotion
He is a biomedical gerontologist based in Mountain View, California, USA, and is the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process. He is also VP of New Technology Discovery at AgeX Therapeutics, a biotechnology startup developing new therapies in the field of biomedical gerontology. In addition, he is Editor-in-Chief of Rejuvenation Research, the world's highest-impact peer-reviewed journal focused on intervention in aging.
He received his BA in computer science and Ph.D. in biology from the University of Cambridge. His research interests encompass the characterisation of all the types of self-inflicted cellular and molecular damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage.
Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organisations.
He is a highly sought-after speaker who gives 40-50 invited talks per year at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public.
Advisor in Health and Social Security Policy, Longevity and Aging Studies, Primary Care, Government Affairs and Lobbying, Strategic Planning and Entrepreneurship, Media and Public Relations, Legal and Regulatory Affairs
Edwina Rogers has served in public policy positions in the US Senate, White House, private and international sectors for over twenty years. Edwina is currently the C.E.O. of The Global Healthspan Policy Institute (GHPI). GHPI is a Washington-based think tank and international coalition dedicated to extending the time period that humans are healthy through measuring and managing aging and age-related diseases.
Previously she served as the Executive Director at the Secular Coalition for America (SCA), a non-profit coalition that represents the diverse and growing voice for separation of religion and government. She served as the founding Executive Director of the Patient-Centered Primary Care Collaborative from 2006-2011, a Washington DC trade association, responsible for the national Patient-Centered Medical Home movement and implementing the model around the US. Edwina served as Vice President, Health Policy for The ERISA Industry Committee (ERIC) in Washington, DC from May 2004 until January 2009. ERIC advocates the employee benefits and compensation interests of America's major employers.
Edwina has been a public policy expert for over twenty years and has worked for two Presidents and four Senators. She was an Economic Advisor for President George W. Bush at the White House during 2001 and 2002 at the National Economic Council, focusing on health and social security policy. Ms. Rogers was General Counsel of the National Republican Senatorial Committee during the Republican take-over of the Senate in 1994. She worked for Senator Lott while he was Majority Leader in 1999 and she handled health policy for Senator Sessions in 2003 and 2004. Edwina worked on International Trade matters for President Bush at the Department of Commerce from 1989 until 1991. She received her BS in Corporate Finance from the University of Alabama and a JD from Catholic University in Washington DC. Ms. Rogers was a Fellow at the Kennedy School at Harvard during 1996.
She served on the Board of Directors of Semco Energy, Inc. (NYSE: SEN) a natural gas distribution company.
Edwina has been a regular contributor of conservative newspaper columns, health and policy journals and a regular strategist on cable news television.
Advisor in Clinical Epidemiology, Biostatistics, Advanced Data Analysis, Diagnostic Algorithms, Machine Learning in Medicine, Legal and Regulatory Affairs
Sviatoslav is a biostatistician, public health specialist, and educator, specializing in Biostatistics, Mathematical Modelling and Lifestyle Risk Factors Assessment including those for infectious (HIV/AIDS) and non-communicable diseases.
Dr. Plavinski completed study at the First Medical Institute named after Pavlov there (Medical Doctor degree). He has received training at Erfurt Medical Academy (Germany) before moving to full-time research position at the Institute for Experimental Medicine where he earned his Ph.D. degree. Main focus of his interest in 1990s was cardiovascular diseases and reasons for rapid increase in mortality in Russia in 1990s. In 1998 he joined Medical Academy for Postgraduate Studies where he earned D.Sc. degree and became Dean of the College of Public Health and participated in numerous international projects. Focus of his interests moved to risk factors of infectious diseases, first of all HIV/AIDS and STI, with accent on statistical aspects of risk studies.
He was an expert for the Russian delegation at G8 summit in 2006 and 2014, Baltic Sea Communicable Disease Task Force, St. Petersburg city commission on health care quality. He did expert work for WHO and UNDP. Dr. Plavinski is a Board member of the Open Health Institute – largest Russian non-profit organization leading preventive efforts against HIV/AIDS among vulnerable population.
Dr. Plavinski's research interests include modelling infectious diseases spread, quality improvement in area of preventive work and evidence-based assessment of prevention effectiveness and cost-effectiveness. He is very much interested in health law, especially public health laws and its influence on risk behaviour.
He is an author and co-author of more than 250 research publications, including several monographs. Dr. Plavinski reviewed articles for J. Epidemiol., Social and Behavioral Medicine, BMJ, Social Science in Medicine and is a member of editorial board of several Russian medical journals.
He actively worked in the field of Clinical Trials and Health Technologies Assessment, as biostatistician and modeller. He is long-term user and author of several books on such statistical systems as SAS and R.
Sviatoslav is an author and co-author of 270 research articles, chapters and monographs, including articles in British Medical Journal (2003, 2005) and monographs 'Biostatistics. Analysis of Biomedical Data with SAS System' (2005), "Introduction to Biostatistics for Medicine"(2011), "Variants of drug provisions for Russia. Lessons from Europe and other countries" (with V. Vlassov, 2013) [in Russian].
He is an Editorial board member: Russian Family Physician Journal, Herald of the North-West State University, HIV-infection and Immunosuppression.
Prof. Plavinski reviewed articles for: J Epidemiol., Social and Behavioral Medicine, Social Science in Medicine, BMJ. He is a statistical reviewer for Psychopharmacology and Biological Narcology Journal.
Dr. Plavinski is currently Chief Academic Officer at the North-West State Medical University, Saint-Petersburg, and Chair of the Department of Teaching, Philosophy and Law there. He also teaches courses for Master of Public Health students and fellowship students of other specialities as well as physicians.
Advisor in Aging and Longevity Studies, Genetics and Genomics, Therapy and Prevention of Ameliorate Age-Related diseases, Technological Trends, Transhumanism
João Pedro graduated in Microbiology in 1999 from the Escola Superior de Biotecnologia in his hometown of Porto, Portugal, and in 2004 obtained a PhD in Biological Sciences from the University of Namur in Belgium. Following further training in computational biology and genetics at Harvard Medical School (Boston, USA), in 2008 Dr. de Magalhaes joined the University of Liverpool in the UK as a faculty member to develop his own group on genomic approaches to ageing.
His research on genetics, ageing and longevity has widely been featured in scientific magazines (Science, Nature, Scientific American, New Scientist, etc.).
In addition, he has a long-term interest in technological trends and their future impact on society. His work on predicting how technology will shape the human condition has been published in magazines such as Futures and The Futurist, and in newspapers like The Independent.
Dr de Magalhaes has given over 100 invited talks, including a TEDx talk, and makes regular media appearances (BBC, CNN, the Washington Post, the Financial Times and many others). He is also an advisor/consultant for various organizations, including nonprofit foundations and biotech companies.
Advisor in Clinical Genetics, Aging and Longevity Studies, Biochemistry, Neurobiology, Biotechnology
Professor, Ph.D., D.Sc. (IISc), FAS-AP, FAMS, FNASc, FNA.
He is an Indian National Science Academy Honorary Scientist, working at the School of Medical Sciences, University of Hyderabad, India.
He has worked as a Professor of Biochemistry / Neurobiology at the University of Hyderabad, and as an INSA-Senior Scientist / Honorary Scientist & Professor at the Centers for Biotechnology and Innovative Research, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukatpally, Hyderabad.
His research interests include Biochemistry and Molecular Biology of the developing and aging brain with special reference to DNA-damage and its repair. He has more than 120 research publications in national and international journals and books. His contributions include establishing the link between aging and decreased DNA repair, particularly the base excision repair, in the brain.
He is presently working on a monograph containing the latest scientific information about the process of aging in higher organisms and also examining the available related traditional Indian (Vedic) concepts. He has advocated for the establishment of Institutes or Centers for multidisciplinary scientific study of the phenomenon of aging and the associated diseases in India.
Advisor in Financial Management, Business Models, Coaching, Project Management, Risk Assessment, Investment Strategy, Business Development
Victor is the Founding partner and CEO of consultancy company (est. 2003) working in the field of investment projects evaluation and strategy development. He also presents his practical-oriented trainings for top-managers, corporate specialists and governmental officials, also teaches at leading business schools of Russia and Kazakhstan, accredited by AMBA, as an invited professor. He is a full member of geopolitics and national security branch of Russian academy of natural sciences (RAEN).
Victor is a member of National association of independent directors. He is a member of the Commission for consultancy and financial audit at the All-Russian Public Organization "Opora Rossii", largest association of Russian SME.
He received Ph.D. in Robotics, AI and Control Systems at the Bauman University and passed through training programs at IESE Business School (Spain), Kingston BS (Great Britain), Schulich School of Business (Canada) for top-management education.
He currently works at Bauman University at the professional development department of Institute for Modern Educational Technologies. He is an expert in assessment and training professional competencies, especially in the area of corporate governance, corporate strategy, managing innovation and investment projects. He fulfilled a variety of scientific research and consultancy projects for governmental bodies, corporations and companies. Now he is a mentor of several innovation technology start-ups.
- Pre-ICO + Private Placement (2%)
- ICO, Round I (25%)
- ICO, Round 2-3 (55%)
- EHF Team + Bounty Campaign + Marketing + Strategic Investors (18%)
Cost of the token1 token for 0.006 $
Price without discounts
+0.25% Daily price increment
Rate the project
Estimate the project on a five-point scale or switch to the simple scale
Estimate the project on a simple scale or switch to the five-point scale
Relevance of the problem and Market size
Founders, Team & Advisors
Budget allocation and roadmap
Token economy, Tokenization & Business model
Distribution & Lock up of tokens, Discounts for early buyers
Summary rate the project
Rate the project by other users8
The presentation is good. There are publications in press. The project seems attractive at this stage.
Risks and disadvantages
The Whitepaper contains the information about key technologies and it looks like a research. But according to the roadmap the project starts in March 2018. It rases some doubts... What time does it take to do a research? And why the roadmap shows that the project exists since March 2018? Maybe because the information about key technologies has nothing to do with a research and it was written in a couple of days? Or maybe the team just doesn`t want to mention for how long the project exists while nobody is doing any real work? I would like to understand...
The project is really very interesting. Because of it`s idea. It is an attractive thing to have the whole clinic in a mobile phone. But it looks like this project lacks transparency.
A very detailed, revealing and understandable presentation describing the concept, vision, business model. And even honestly description of the possible market risks.
it seems, the team has provided all possible scenarios for the development of the narrative.
An expanded business plan and budget.
The price of a monthly subscription is not so high.
Experienced and professional team members and advisers.
Risks and disadvantages
Traffic statistics are low, and shows that interest for the project is falling in recent months. Not a very good indicator.
The project looks interesting and reliable, a lot of work has been done on the documentation and presentation, but confuses that there are no working samples, a beta version of the platform or smth
Accepts 2 main crypto-currencies and fiat, so can become a convenient, universal investment for different groups of investors.
All team members have a serious professional background.
Risks and disadvantages
Dynamics of traffic shows perhaps not very good work on marketing.
Competitive advantages of the business model are described vaguely and superficially, and the goals sound a bit like science fiction for me. I'm not sure about this project.
The project accepts major cryptocurencies in the current market this factor creates distributed value of the token, making it less pron to risk of loss and also entices investors with different cryptocurrencies to invest. The bounty program offers tokens to those carrying out marketing and referral campaigns which will increase the popularity. The project offers bonuses to the early investors, this will attract many investors to take advantage of such an opportunity. The road map is detailed and well elaborate. Some of the founder team members have experience in the cryptocurrency market which will enable them make some critical decisions in the companies favor propelling it to success.
Risks and disadvantages
The project has a delayed period of road map execution this affects the image of the team and also makes the project less profitable, the crypto market is volatile and at the same time policies and market structures changeover time. The weakness of the PR team is shown in the low traffic statistics displayed from the various search engines this will result into failure to achieve the desired hard cap, it will also prohibit the capable investors from investing in the project.
The project should look into getting a dynamic team of advisers better service delivery and also to have the job done efficiently the project has a brilliant initiative but the current target market might not be ready for such advances in the health sector therefor it might take a long term period to adopt this business model effectively.
The project can help many people. I suppose the platform (if ever released) can attract a lot of users.
Risks and disadvantages
A lot of work is planned to be done and it will take a long period of time. Since the development is not started yet, it will be difficult to meet the goals.
The project is very interesting. The Whitepaper is available in 18 languages and contains a lot of information. Still it is risky to invest in the project where nothing is done yet being awared about competition in this field.
Not the first one project with such idea in the basement, however has a bit more expanded functional compare to the other. Very detailed presentation and text.
Risks and disadvantages
Competitors exist already in the open ICOs. Plenty of remarks and question signs about the text. Why patience should correct their medical records, what qualifications they have for that? Self-medication another amazing idea which will lead to total chaos. Phrase "Do all the doctors really want to constantly learn, maintain a high professional level and help patient in the most effective way?" sounds rude, offensive and humiliating for medical society and automatically put patients in aggressive mode. Where the hell did the project team got information about medical prescriptions based on one's own experience, believes and etc. which do not have sufficient evidence of efficacy and safety? In what country of the world do they live? Experiments on human beings are still allowed there? Probably they forgot that at least it is unlawful and can cost doctor his license.
Looks like there are really many specialists in the team but with total lack of competence or ethics in the question. Competition is good and impressive presentation is even better but respect to others and using the real fact is better. On top of that never should be proposed provocative ideas which are helpful in getting popularity but dangerous for patients. If to choose from the range of the similar projects definitely not this one.
There are the competent team of the project, many specialists with medical education, many programmers with experience in developing the blockchain. Also there is transparent token distribution scheme and detailed roadmap.
Risks and disadvantages
As the project is very large-scale and expensive, it takes a lot of investment and time to implement it. There are risks of not coping with the project or not getting the necessary amount of investment.
Based on the advantages and risks of the project, I can say that the creation of the madical IT platform with blockchain is a very promising and useful solution, but there is a very big complexity of implementation. If the team makes every effort, the project will be successful.
The project is more like a remote hospital and an efficient one. This will increase life expectancy of many people. their is transparency in payment methods with the use of blockchain and cryptocurrency.
The project allows major cryptocurrencies with a number of users and adopting will be quite easy.Health is important and this project offers limitless solution to keep it in shape
Risks and disadvantages
The project is looking at storing health patterns of many individuals on servers which might breach confidentiality of individuals health records.
It will require individuals to have knowledge of medication in order to carry out self medication which they cant entirely do on their own.
For the busy world and the busy people out their this could be an alternate solution to look out for symptoms before they result into signs.Many doctors at various health services don't usually do efficient diagnosis Eheaith-first is the ultimate solution.